Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Moderate Buy" from AnalystsMarket Beat·2 days ago, 01:14 AMURGN-4.31%
Analyst Sees Strong Zusduri Upside, Lifts UroGen Pharma Price Target from $35 to $50 with Buy RatingTip Ranks·Jul 21 at 01:58 PMURGN-4.31%
What UroGen Pharma (URGN)'s UGN-501 IND Clearance Means For ShareholdersSimplywall·Jul 21 at 12:04 AMURGN-4.31%
Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027Barchart Option·Jul 17 at 09:15 AMURGN-4.31%
UroGen says USPTO allows new patent claims for ZUSDURI, UGN-103 through July 2044PUBT·Jul 15 at 07:02 AMURGN-4.31%
UroGen says FDA clears IND for UGN-501 oncolytic virus in bladder cancerPUBT·Jul 8 at 07:03 AMURGN-4.31%
5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses?rttnews·Jul 6 at 04:55 AMURGN-4.31%CLYM-0.83%
UroGen Pharma CMO Mark Schoenberg disposes of $350,100 in common sharesPUBT·Jun 24 at 09:24 AMURGN-4.31%
UroGen Pharma shareholders approve amended articles of association at annual meetingPUBT·Jun 23 at 03:15 PMURGN-4.31%
How Resolving Jelmyto Patent Litigation And Setting 2030 Generic Entry At UroGen Pharma (URGN) Has Changed Its Investment StorySimplywall·Jun 9 at 04:29 AMURGN-4.31%TEVA-1.67%
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | URGN Stock NewsStockTitan·Jun 1 at 07:10 AMURGN-4.31%
